In turn, the company—which is broadly seeking to develop inflammatory drugs targeting the complement system—anticipates ...
While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...
While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback